Replimune Group (NASDAQ:REPL) Shares Gap Down – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped down before the market opened on Friday . The stock had previously closed at $11.13, but opened at $10.22. Replimune Group shares last traded at $10.8860, with a volume of 1,562,034 shares changing hands.

Analyst Ratings Changes

REPL has been the subject of several recent analyst reports. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Finally, HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Seven research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Replimune Group presently has a consensus rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Trading Down 1.6%

The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $6.05 and a 200-day moving average price of $7.27. The company has a market capitalization of $904.01 million, a price-to-earnings ratio of -3.19 and a beta of 0.91.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Replimune Group

A number of large investors have recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after acquiring an additional 6,653 shares in the last quarter. Millennium Management LLC lifted its position in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers grew its position in Replimune Group by 6.9% during the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Replimune Group by 149.5% during the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.